DEA: Medical Cannabis Firms Must Trade Only With Registered Companies

Medical cannabis businesses hoping to benefit from the federal government's rescheduling changes now have a clear deadline to work toward. The Drug Enforcement Administration has issued new guidance saying that companies that want federal registration and the protections attached to it under the Trump administration's reform need to adjust their supply chains by late November.

The core requirement is about who a business does business with. By that deadline, a company is expected to begin sourcing cannabis only from other companies that have either been granted federal registration or applied for it in a timely fashion. The same standard applies in the other direction, meaning businesses should also be supplying only to companies that meet that description. In effect, the agency is asking the industry to build a closed loop of registered or properly pending participants.

For operators, this could be a significant operational shift. Cultivators, processors and dispensaries that currently work with a wide range of state-licensed partners may need to review every vendor and customer relationship to confirm where each stands in the federal process. A partner that missed the timely application window, or never applied, could become a liability for a business that wants to keep its own registration in good standing.

The guidance also underscores that federal registration is not just a one-time form to file. It comes with ongoing expectations about how products move through the market. Companies that want the protections will have to treat compliance as part of daily business, from purchasing decisions to sales agreements.

Patients shouldn't expect an immediate change at the dispensary, but the months leading up to the late November cutoff may be busy behind the scenes. Businesses will be sorting out contracts, checking registration status and deciding whether the benefits of federal protection are worth reshaping how they operate.